<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940573</url>
  </required_header>
  <id_info>
    <org_study_id>CA007</org_study_id>
    <nct_id>NCT03940573</nct_id>
  </id_info>
  <brief_title>Pursuit: Real World Use of the Eclipse System</brief_title>
  <acronym>PURSUIT</acronym>
  <official_title>A Registry to Further Develop the Understanding of the Real World Use of the Eclipse System for Fecal Incontinence in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pelvalon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pelvalon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open label post-market registry to collect Patient Reported Outcomes and
      Fitting metrics (e.g. sizes used) in subjects using the Eclipse System in a commercial
      setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 150 subjects enrolled, in up to 25 sites. Population of all adult female patients with
      Fecal Incontinence (FI) who present at, or are identified at, participating sites are
      eligible. This includes patients who are newly prescribed Eclipse, and those already using
      Eclipse who return for an annual renewal visit during the enrollment period.

      Includes fitting of the patient for the Eclipse System with collection of relevant health
      history data. Patients are provided a temporary device for a trial usage period. Multiple
      device sizes may be attempted to find the correct fit for the patient, at which point the
      patient is provided with the long term use Eclipse Insert and enters the treatment period.

      During the fitting and treatment period, patient experience will be assessed by surveys, St.
      Mark's (Vaizey) scores, and the validated global PGI-I index (Patient Global Impression of
      Improvement). Surveys will be perform at the fitting follow up and at 12 months of device
      usage, and optionally at 3, 6, and 9 months of device usage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fit Rate</measure>
    <time_frame>Data collected at fitting visits (max 3 attempts), 5-7 weeks from initial screening</time_frame>
    <description>Proportion of patients successfully fit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device Size Distribution</measure>
    <time_frame>Data collected at fitting visits (max 3 attempts), 5-7 weeks from initial screening</time_frame>
    <description>Size distribution of devices among successfully fit patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>St. Mark's Score (Vaizey)</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in mean scores (scored 0-24 with 0 = total continence and 24 = total incontinence)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PGI-I Score</measure>
    <time_frame>12 months</time_frame>
    <description>Patient global impression of improvement score (7 point scale comparing current condition to baseline, from 1 = very much better to 7 = very much worse)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>St. Mark's Score (Vaizey)</measure>
    <time_frame>3 months</time_frame>
    <description>Change from baseline in mean scores (scored 0-24 with 0 = total continence and 24 = total incontinence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. Mark's Score (Vaizey)</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in mean scores (scored 0-24 with 0 = total continence and 24 = total incontinence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. Mark's Score (Vaizey)</measure>
    <time_frame>9 months</time_frame>
    <description>Change from baseline in mean scores (scored 0-24 with 0 = total continence and 24 = total incontinence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGI-I Score</measure>
    <time_frame>3 months</time_frame>
    <description>Patient global impression of improvement score (7 point scale comparing current condition to baseline, from 1 = very much better to 7 = very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGI-I Score</measure>
    <time_frame>6 months</time_frame>
    <description>Patient global impression of improvement score (7 point scale comparing current condition to baseline, from 1 = very much better to 7 = very much worse)e</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGI-I Score</measure>
    <time_frame>9 months</time_frame>
    <description>Patient global impression of improvement score (7 point scale comparing current condition to baseline, from 1 = very much better to 7 = very much worse)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients fitted with the device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eclipse Insert</intervention_name>
    <description>Rectal Control System.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult female

          2. Diagnosis of Fecal Incontinence

          3. Clinician recommendation of the Eclipse System

          4. Subject provides informed consent and HIPAA authorization

        No Exclusion Criteria.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Pettit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steve Herbowy</last_name>
    <phone>6507966294</phone>
    <email>Steve@pelvalon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jared Goor, PhD</last_name>
    <phone>8582203876</phone>
    <email>jared@pelvalon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The American Association of Female Pelvic Medicine</name>
      <address>
        <city>Agoura Hills</city>
        <state>California</state>
        <zip>91301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Louis</last_name>
      <phone>818-991-0988</phone>
    </contact>
    <investigator>
      <last_name>Sherry Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ob-Gyn and Incontinence Center</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kumar Kothandaraman</last_name>
    </contact>
    <investigator>
      <last_name>Prema Kothandaraman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Beach Urogynecology</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dara France</last_name>
      <phone>562-426-4904</phone>
    </contact>
    <investigator>
      <last_name>Jocelyn Craig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Urogynecology, LLC</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene Jones</last_name>
      <phone>904-652-0373</phone>
    </contact>
    <investigator>
      <last_name>Jason Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Pettit, MD</last_name>
      <phone>904-953-2977</phone>
      <email>paul.pettit@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princeton Urogynecology</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Shaltis</last_name>
      <phone>609-924-2230</phone>
    </contact>
    <investigator>
      <last_name>Heather van Raalte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://eclipsesystem.com/</url>
    <description>Pelvalon, Eclipse manufacturer and Study Sponsor, website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03940573/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

